$1.15
-0.06 (-4.96%)
Open$1.19
Previous Close$1.21
Day High$1.21
Day Low$1.14
52W High$8.08
52W Low$1.01
Volume—
Avg Volume637.5K
Market Cap31.41M
P/E Ratio—
EPS$-6.70
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,809.6% upside
Current
$1.15
$1.15
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.44M | 1.21M | 5.52M |
| Net Income | -156,363,504 | -118,158,819 | -589,967 |
| Profit Margin | -10,887.4% | -10,343.0% | -10.7% |
| EBITDA | -120,082,146 | -95,783,407 | -924,468 |
| Free Cash Flow | — | — | -774,673 |
| Rev Growth | +19.1% | +19.1% | -1.7% |
| Debt/Equity | 1.21 | 1.21 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |